Chris had been taking NMN for eight months when a colleague asked him what it was. “NAD+ precursor,” Chris said. “Anti-aging supplement.” Blank look back. “Does it work?” Chris paused. He’d been paying $80 a month for a product he’d first read about in a breathless tech magazine profile of a Silicon Valley longevity clinic. He’d felt something. More energy, maybe. Better recovery. But was that the NMN, or the fact that he’d started sleeping more consistently around the same time? He realized, standing there, that he genuinely couldn’t answer the question.
That moment of honest uncertainty is exactly where most people land in the NMN/NR supplement space. There’s real science here — more than for most supplements on the market, worth saying up front. But there’s also a significant gap between what the animal data shows and what’s actually been demonstrated in humans, and a vast marketing apparatus that’s moved well ahead of the evidence in making promises to people like Chris.
Here’s the honest, evidence-based assessment of NAD+, NMN, NR, and the science underneath them.
What Is NAD+ and Why Does It Decline
Beyond energy metabolism, NAD+ is the essential substrate for two classes of enzymes critical to aging biology: sirtuins (SIRT1-7) and PARPs (poly-ADP-ribose polymerases). Sirtuins are NAD+-dependent deacetylases regulating gene expression, DNA repair, mitochondrial biogenesis, stress resistance, and metabolic adaptation — essentially a master regulatory circuit for the cellular adaptations associated with caloric restriction and longevity. PARPs are NAD+-consuming enzymes critical for DNA repair. When DNA damage rises, as it does with aging and oxidative stress, PARPs burn through massive amounts of NAD+ in repair attempts, contributing to the overall depletion.
The decline of NAD+ with age is well-documented and substantial. Shinichiro Imai’s laboratory at Washington University School of Medicine, among others, has documented NAD+ levels in tissues dropping by roughly 50% between early adulthood and middle age, with the decline starting as early as the late twenties and accelerating through the forties. By age sixty, tissue NAD+ levels in many organs sit at 30-50% of what they were at twenty.
The causes of age-related NAD+ decline are multiple: increased PARP activity consuming NAD+ (from accumulating DNA damage), increased CD38 activity (another NAD+-consuming enzyme upregulated by inflammation), reduced efficiency of NAD+ synthesis pathways, and possibly changes in the gut microbiome affecting dietary precursor availability. The result of declining NAD+ is impaired sirtuin function, reduced mitochondrial efficiency, diminished DNA repair capacity, and worsening metabolic regulation — all of it feeding into the aging phenotype together.
NMN and NR: The Two Primary NAD+ Precursors
NAD+ itself can’t be meaningfully supplemented directly — it doesn’t enter cells efficiently. So the strategy instead is supplementing precursor molecules that get converted into NAD+ intracellularly. The two most studied precursors are NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside).
NMN sits one step upstream from NAD+ in the biosynthesis pathway: NMN → NAD+. The conversion is fast and efficient in most tissues. NR sits two steps upstream: NR → NMN → NAD+. Both compounds have to enter cells to be converted, and both appear to do so through different transporter mechanisms. Which one is more effective at raising tissue NAD+ in humans remains genuinely unsettled.
NMN got popularized largely through the work of David Sinclair at Harvard Medical School and Shinichiro Imai at Washington University. Imai’s mouse studies, published in Cell Metabolism in 2013, showed NMN supplementation could reverse multiple age-related physiological declines in elderly mice: improved energy metabolism, muscle function, bone density, insulin sensitivity, and extended lifespan in some strain-specific studies. Remarkable results. They generated enormous excitement and, soon after, enormous commercial investment.
NR was developed partly through the work of Charles Brenner and commercialized by ChromaDex under the brand name Tru Niagen. NR has the advantage — at time of writing — of being the more extensively studied of the two in humans, with multiple clinical trials showing that oral NR safely and significantly raises NAD+ levels in blood and tissues.
The first serious human trial of NMN came from Jun Yoshino et al., published in 2021 in Science. Randomized, placebo-controlled, enrolling premenopausal women with prediabetes who were overweight or obese. Ten weeks of NMN supplementation (250mg/day) significantly increased NAD+ metabolite levels in skeletal muscle, improved muscle insulin sensitivity, and favorably affected some gene expression pathways tied to muscle energy metabolism and aging. Important proof-of-concept: NMN does raise NAD+ in human muscle tissue, and that elevation appears to carry measurable metabolic effects.
What the Human Evidence Actually Shows
The honest accounting of the human evidence for NMN and NR runs like this: these supplements reliably raise NAD+ levels in blood and in some tissues. They appear safe at trial doses (250-500mg NMN, 300-1000mg NR daily). They’ve produced some measurable improvements in specific metabolic parameters in specific populations in clinical trials. What they have not yet shown: extended human lifespan, significantly improved age-related functional decline in general healthy adult populations, or anything close to the dramatic anti-aging effects seen in mouse studies.
The human trial evidence for NR includes a study by Martens et al. (Cell Metabolism 2018) finding 6 weeks of NR supplementation (1000mg/day) increased blood NAD+ by roughly 60% and decreased blood pressure and arterial stiffness in middle-aged and older adults — a promising cardiovascular signal. A trial in kidney transplant patients showed NR reduced markers of kidney tubular injury. Several studies in exercise and athletic populations showed some, though inconsistent, improvements in endurance performance and recovery.
For NMN, the 2021 Yoshino trial remains the most rigorous human study. A Japanese trial by Yamaguchi et al. in 2022 found 250mg/day NMN for 12 weeks improved muscle function and gait speed in older adults (60-70 years) versus placebo — a clinically meaningful outcome that, if replicated, would mark a significant demonstration of functional benefit. A trial by Liao et al. found improvements in muscle strength and performance in recreational runners taking NMN.
The important context: these trials, while interesting and mechanistically plausible, are small and short in specific populations. They demonstrate biological effects of NAD+ precursor supplementation. They fall well short of establishing that NMN or NR meaningfully slows aging or reduces age-related disease risk in healthy adults over long time periods. The effects shown in animal models — truly dramatic reversals of aging phenotypes — haven’t been reproduced at equivalent magnitude in human studies. Not surprising, honestly. The translational gap between mouse models and humans in aging research is well-established, and nobody should expect direct translation of rodent longevity results into human ones.
The honest position on NAD+ precursors is: they have biological plausibility, safety, and some human evidence of metabolic benefit — particularly in older or metabolically compromised individuals. They do not have human evidence of longevity extension or dramatic anti-aging effects. They are worth considering as adjuncts in a comprehensive longevity strategy, but they are not the foundation of one.
The Dose Question and Bioavailability
Doses used in human clinical trials range from 250mg to 1000mg per day for both NMN and NR. The optimal dose remains unknown and likely varies by individual factors — age, baseline NAD+ status, genetic variation in NAD+ metabolism, health status. Older adults and those with metabolic dysfunction (obesity, insulin resistance, diabetes) likely carry more severely depleted NAD+ — and those are the groups where trials have picked up the clearest signals.
The bioavailability question — whether orally consumed NMN actually reaches peripheral tissues and not just blood — has been a genuine point of controversy. An early study suggested orally consumed NMN was degraded to nicotinamide before absorption and reconverted to NAD+ via a different pathway entirely. The 2021 Yoshino study addressed this directly, measuring NMN metabolites in skeletal muscle (not just blood) and showing NMN really does elevate NAD+ in muscle tissue — not just circulating blood levels.
Sublingual NMN — dissolved under the tongue for direct bloodstream absorption, bypassing gut metabolism — has been advocated by some practitioners as offering superior bioavailability, and there’s mechanistic logic behind it. But head-to-head comparison of sublingual versus oral NMN in humans hasn’t been rigorously conducted in peer-reviewed research, so this remains largely theoretical for now.
Liposomal formulations of NR and NMN claim improved bioavailability through encapsulation in lipid vesicles. Some in vitro data supports the claim, but rigorous human bioavailability comparisons against standard oral forms haven’t been published as of this writing. The premium price for liposomal forms deserves appropriate skepticism until comparative human data actually shows up.
Safety Profile: What We Know
A theoretical concern worth flagging: NAD+ precursors feed the same biosynthesis pathway as niacin (vitamin B3), and very high niacin doses are associated with flushing. NMN and NR at typical supplement doses don’t typically cause flushing, since they enter the NAD+ pathway at different points than pharmacological niacin doses do. Still, some practitioners report individuals experiencing flushing at high-dose NR.
The cancer question deserves honest discussion. NAD+ is required for the growth of virtually all rapidly dividing cells — including cancer cells. Several research groups have studied whether elevating NAD+ could accelerate cancer growth. In mouse models, the answer’s been context-dependent: NAD+ elevation didn’t appear to promote new tumor formation, but did accelerate growth in some established tumor models when supplementation started after tumor induction. A theoretical concern, not demonstrated in human clinical trials or observational studies, but it’s why some practitioners recommend against NAD+ precursor supplementation in people with active cancer or a recently treated cancer history — at least until more data is in.
Lifestyle Strategies to Support NAD+ Without Supplementation
Before opening the wallet for expensive NMN or NR, it’s worth understanding the lifestyle interventions that reliably support NAD+ levels and sirtuin activity — because these are both free and well-established in humans.
Exercise is the most powerful lifestyle NAD+ booster there is. Aerobic exercise activates AMPK (the cellular energy sensor) and increases NAD+ utilization, which upregulates salvage pathway enzymes that recycle NAD+ more efficiently. Regular aerobic training raises NAD+ levels and sirtuin activity in muscle tissue — a well-documented effect in both animal and human studies. A study by Canto et al. showed exercise raises muscle NAD+ comparably to NR supplementation in mice, and human data support the finding that trained individuals carry higher baseline skeletal muscle NAD+ than sedentary individuals.
Caloric restriction and time-restricted eating activate sirtuins partly by increasing the NAD+/NADH ratio — the energy-depleted state fasting creates signals sirtuins to switch on adaptive stress responses. One mechanism by which intermittent fasting produces its metabolic and potentially anti-aging effects.
Heat exposure — sauna use — has been shown to increase NAD+ in some tissues through heat shock protein-mediated mechanisms. Regular sauna use (4-7 sessions weekly at 80°C for 20 minutes, the pattern used in Finnish population studies) associates with substantially reduced cardiovascular and all-cause mortality, with plausible NAD+ and sirtuin pathway contributions sitting alongside the direct cardiovascular conditioning effect.
Dietary sources of NAD+ precursors include niacin-rich foods: meat, fish, poultry, mushrooms, and peanuts all provide nicotinamide and nicotinic acid, convertible to NAD+ via the Preiss-Handler and salvage pathways. Tryptophan (turkey, eggs, cheese, nuts) can be converted to NAD+ via de novo synthesis. A varied diet with adequate protein supplies the raw materials for NAD+ synthesis, though at lower concentrations than supplemental NMN or NR provide.
NMN vs NR: How to Choose
The NMN versus NR question is genuinely unresolved scientifically, and the supplement industry’s confident claims that one clearly beats the other aren’t supported by comparative human data. A few things can be said with some confidence, though:
NR has more published human clinical trial data as of 2026, making it the more extensively characterized supplement in terms of human safety and bioavailability. The most-studied human dose is 1000mg/day. NR has generally been shown to significantly raise blood NAD+ metabolites and has produced some cardiovascular and metabolic benefits in trial data.
NMN has fewer but still compelling human trials (the Yoshino 2021 study showing muscle tissue NAD+ elevation, the Yamaguchi 2022 study showing functional improvement in older adults). NMN sits structurally one step closer to NAD+ in the biosynthesis pathway, which could theoretically provide an advantage in tissues where the NR kinase step is rate-limiting. NMN typically costs more than NR per equivalent dose.
Practical recommendation: if cost is a real constraint, NR is the more economical choice and has the more established human trial base behind it. Willing to invest in NMN instead? Buy from a reputable, third-party-tested brand — purity varies more than potency in this category. Taking either in the morning — aligned with circadian NAD+ synthesis patterns — and combining it with the lifestyle NAD+ optimizers (exercise, time-restricted eating) maximizes the total effect.
The NAD+ Restoration Protocol
The NAD+ Restoration Protocol is a four-component framework for supporting optimal NAD+ status through the combination of lifestyle, nutrition, and targeted supplementation — prioritized by evidence strength and cost-effectiveness.
Component 1 — Exercise Consistency: The foundation. 4-5 sessions weekly of aerobic exercise (at least 150 minutes in zone 2) as the strongest lifestyle-based NAD+ elevator. Add 2-3 weekly resistance training sessions for the complementary metabolic effects. Non-negotiable before any supplement consideration whatsoever.
Component 2 — Metabolic Environment: Time-restricted eating (8-10 hour eating window, 14-16 hour overnight fast) to create the fasting-mediated AMPK activation and NAD+/NADH ratio shifts that support sirtuin activity. Adequate dietary protein (1.2-1.6g/kg/day) to support de novo NAD+ synthesis from tryptophan. Regular niacin-containing foods (meat, fish, mushrooms). Avoid excess alcohol — alcohol directly competes with NAD+ by generating NADH via alcohol dehydrogenase, disrupting the NAD+/NADH ratio.
Component 3 — NAD+ Precursor Supplementation: This is where a precursor — NR or NMN — enters the picture, and the case for it is strongest in the groups the trials actually studied: adults past midlife and people with metabolic dysfunction, where NAD+ biosynthesis capacity is already declining. Pairing a precursor with pterostilbene or resveratrol is the move if sirtuin activation is the goal, since those compounds activate SIRT1 and need NAD+ as substrate to do it. How much of any of it is worth taking is unsettled even in the literature, and worth working out with a clinician rather than off a label.
Component 4 — CD38 Inhibition: CD38 is an NAD+-consuming enzyme dramatically upregulated by inflammation. Reducing chronic inflammation through all available means (exercise, anti-inflammatory diet, weight management, sleep quality) reduces CD38 activity and eases the drain on NAD+. Quercetin and luteolin have shown CD38 inhibitory activity in laboratory studies, and supplementing them as part of a broader polyphenol strategy may help protect NAD+ levels by reducing CD38-mediated consumption.
FAQ
- Will NMN or NR actually make me live longer? No human evidence exists that these supplements extend lifespan. The animal evidence is compelling, but the translational record from mouse longevity interventions to human outcomes is poor. What human evidence exists suggests potential metabolic benefits, particularly for older or metabolically compromised individuals. Taking NMN or NR hoping for dramatic life extension based on mouse data? Recalibrate expectations while the human trial data matures.
- How quickly does NAD+ increase after starting NMN or NR? Blood NAD+ metabolite levels typically rise significantly within 1-2 weeks of starting supplementation at the intakes trials have used. Tissue NAD+ levels — the clinically more relevant measure — take longer to assess, and were shown to increase in skeletal muscle after 10 weeks in the Yoshino trial. Subjective effects some users report (improved energy, better recovery) would follow the timeline of rising tissue NAD+, roughly 2-6 weeks after starting.
- Can I test my NAD+ levels? Blood NAD+ and NAD+ metabolites can be measured in specialized labs and through some commercial services (companies like Jinfiniti offer direct-to-consumer NAD+ testing). Whole blood NAD+ is the most commonly measured proxy, though skeletal muscle tissue NAD+ is more metabolically relevant and requires biopsy. For most people, the cost and complexity of routine NAD+ testing isn’t warranted — focus on the lifestyle and supplementation practices the evidence supports rather than chasing a specific number.
- Is flushing from NMN or NR different from niacin flush? Niacin (nicotinic acid) flush happens because nicotinic acid activates GPR109A receptors in skin cells, triggering prostaglandin-mediated vasodilation. NMN and NR enter the NAD+ pathway at different points and don’t typically activate GPR109A at standard doses, so flushing is generally not expected and much less common. Some individuals report mild warmth or flushing at high-dose NR, possibly minor pathway spillover into nicotinic acid. Reducing the dose usually resolves it.
- Should I take NMN or NR if I have a family history of cancer? The theoretical concern about NAD+ precursors and cancer relates to NAD+’s role supporting cellular energy metabolism in all rapidly dividing cells, cancer cells included. That said, no clinical trial or large observational study has demonstrated supplemental NMN or NR increases cancer risk in humans. For anyone in active cancer treatment, most oncologists would advise caution about supplements that significantly alter cellular metabolism without established safety data in that specific context. For those with a family history but no active disease, the evidence base doesn’t currently support withholding NAD+ supplementation — but it’s worth a conversation with your oncologist if cancer risk is a specific concern.
- What is the difference between NAD+ and NADH? NAD+ is the oxidized form — the electron acceptor. NADH is the reduced form, after accepting two electrons and a hydrogen ion. In cellular energy metabolism, NAD+ converts to NADH when it accepts electrons from fuel molecules being broken down; NADH then donates those electrons to the mitochondrial electron transport chain, regenerating NAD+ and producing ATP. For longevity purposes, the NAD+/NADH ratio is the key metric — a higher ratio (more oxidized NAD+ relative to reduced NADH) associates with sirtuin activation, better metabolic flexibility, and states resembling caloric restriction. Exercise and fasting both raise the NAD+/NADH ratio.
- How does alcohol affect NAD+ levels? Alcohol metabolism is one of the most potent NAD+-depleting processes in the body, full stop. Ethanol gets metabolized by alcohol dehydrogenase using NAD+ to generate NADH, and acetaldehyde gets further metabolized by aldehyde dehydrogenase, consuming still more NAD+. Heavy drinking can substantially deplete NAD+ in liver cells, impairing sirtuin activity and contributing to alcoholic liver disease through mitochondrial dysfunction and impaired DNA repair. Even moderate regular alcohol consumption shifts the liver’s NAD+/NADH ratio in ways counterproductive to longevity signaling. If supporting NAD+ biology is a priority, minimizing alcohol is one of the most impactful steps available — potentially more impactful than NMN or NR supplementation for regular drinkers.
- Can children or younger adults benefit from NMN or NR? NAD+ supplementation is most mechanistically relevant for people over 40-45, when age-related NAD+ decline becomes significant. For younger adults with good metabolic health and an active lifestyle, the incremental benefit over what exercise and good nutrition already provide is likely minimal. The supplements carry low risk at standard doses, but the cost-benefit is less compelling under 40 compared to optimizing the foundational lifestyle factors first.
- Does David Sinclair actually take NMN? David Sinclair, one of the most prominent researchers in this space, has publicly stated he personally takes NMN among other supplements. Worth noting, weighted appropriately: a researcher’s personal supplement choices aren’t evidence of efficacy — a single N=1 anecdote from someone with clear professional investment in the space. The evidence should drive the decision, not anyone’s self-reported supplementation habits.
The Sirtuins: Why NAD+ Level Matters for Longevity Signaling
SIRT1 is the most studied and has the broadest portfolio of longevity-relevant functions: it deacetylates and activates PGC-1α (the master regulator of mitochondrial biogenesis), FOXO3 (a transcription factor promoting cellular stress resistance and longevity), p53 (regulating whether cells undergo apoptosis or repair in response to DNA damage), and NF-κB (reducing pro-inflammatory gene expression). SIRT1 activation is one of the central mechanisms by which caloric restriction and exercise extend healthspan in animal models — and its NAD+ dependence means declining NAD+ with age is exactly the mechanism by which these adaptive responses get blunted over time.
SIRT3, located in the mitochondrial matrix, regulates mitochondrial protein function and is critical for maintaining electron transport chain efficiency and reducing mitochondrial ROS production. SIRT3 activity protects against age-related cardiovascular disease, cancer, and metabolic dysfunction. In animal models, SIRT3 overexpression extends lifespan, and SIRT3 knockout accelerates multiple aging phenotypes — establishing it as a genuine longevity gene. NAD+ supplementation supports SIRT3 activity, and the mitochondrial benefits of NAD+ precursor supplementation run partly through SIRT3.
SIRT6 regulates genome stability through its role in DNA double-strand break repair, and it controls aging in spectacular ways in animal models: SIRT6 overexpression extends mouse lifespan by 15%, while SIRT6 knockout produces dramatic accelerated aging phenotypes. SIRT6 gets activated by free fatty acids and by NAD+, making the interaction between fasting (which raises free fatty acids), NAD+ status, and genome stability a fascinating area of longevity research with direct practical implications.
NMN in Athletic and Active Populations
One of the more practically relevant emerging applications of NMN sits in exercise performance and recovery — an area where the NAD+-muscle connection is most directly testable and where trial data has started to emerge. The rationale is straightforward: skeletal muscle is among the most metabolically active tissues in the body, with high NAD+ requirements for both ATP generation and sirtuin-mediated adaptations to exercise training. If NMN can support muscle NAD+ levels, it might improve exercise’s metabolic efficiency and the recovery response to training.
EVIDENCE: A randomized controlled trial by Liao et al., published in the Journal of the International Society of Sports Nutrition, found 12 weeks of NMN supplementation (1200mg/day — higher than most consumer products) improved aerobic capacity (VO2max) in amateur runners versus placebo, with particular improvements in “first ventilatory threshold” (the exercise intensity at which breathing becomes labored) and skeletal muscle oxygen utilization efficiency. Mechanistically coherent: better NAD+-dependent mitochondrial function translates into more efficient oxygen use during sustained aerobic exercise.
The timing of NMN supplementation relative to exercise may matter. There’s theoretical rationale for taking NAD+ precursors before exercise (maximizing NAD+ availability during peak metabolic demand) or after (supporting the NAD+-dependent recovery processes including SIRT1-mediated mitochondrial biogenesis). Current evidence isn’t sufficient to definitively establish optimal timing, and most researchers default to morning dosing aligned with the circadian peak of NAD+ synthesis. If NMN or NR is being used primarily for exercise performance, some practitioners recommend timing the dose 30-60 minutes before training — but this remains empirical, not rigorously established.
Tracking NAD+ Status: Practical Biomarkers
For anyone supplementing NAD+ precursors and wanting to check whether it’s producing the desired biological effects, several biomarker strategies exist with different levels of accessibility and clinical utility.
Direct blood NAD+ measurement through commercial services (Jinfiniti’s IntraCellular NAD+ Test uses whole blood to measure intracellular NAD+ in red blood cells, more clinically relevant than the plasma NAD+ metabolites most lab methods measure) provides a direct readout of status. Baseline testing before starting supplementation, followed by retesting at 8-12 weeks, quantifies the response to the specific product and dose being used. Published data suggests optimal NAD+ levels for older adults sit above 40 μM intracellularly, with levels below 20 μM associated with the fatigue, cognitive, and metabolic impairments consistent with severe NAD+ depletion.
Indirect biomarkers reflecting NAD+/sirtuin pathway activity include HbA1c and fasting insulin (SIRT3 activity affects insulin signaling; improvements here may reflect better NAD+-sirtuin function), mitochondrial respiratory function assessments via expired gas analysis (VO2 at lactate threshold), and metabolomic panels including NAD+ metabolites like NMN, NR, nicotinamide, and ADPR (ADP-ribose). Research tools rather than clinical standards, but companies offering precision longevity panels increasingly include some NAD+ metabolite measurements.
Practically, tracking subjective energy levels, sleep quality, exercise recovery speed, and cognitive clarity over the first 12 weeks of NAD+ precursor supplementation gives useful self-reported data — subject to placebo effects, sure, but at least it means something’s being monitored. No subjective improvement after 12 weeks on a quality product at an appropriate dose? Reconsider whether the supplement’s adding value above what lifestyle NAD+ optimization is already providing.
Combining NAD+ Precursors With Other Longevity Supplements
NAD+ precursors don’t exist in isolation in the supplement landscape — they’re often combined with other compounds that work synergistically with the sirtuin pathway or complement the mechanisms of NAD+-dependent aging biology. Understanding the rational combinations helps build a coherent supplementation strategy rather than an undifferentiated pile of capsules.
Resveratrol has a theoretical synergistic relationship with NAD+ precursors: resveratrol is a SIRT1 activator, and increasing SIRT1 activity without adequate NAD+ substrate is like revving an engine with no fuel in it. Conversely, increasing NAD+ without activating SIRT1 leaves the sirtuin pathway underutilized. The combination — NAD+ precursor plus resveratrol or its more bioavailable analog pterostilbene — is the approach David Sinclair personally takes and the Sinclair lab advocates, though human clinical evidence specifically for the combination is limited. Pterostilbene is considerably more bioavailable than resveratrol, which can make it the better value even at a higher price per gram.
Berberine — derived from barberry and goldenseal — activates AMPK through a mechanism different from NAD+ precursors, producing effects on glucose metabolism, insulin sensitivity, and mitochondrial function complementary to NAD+/sirtuin pathway activation. Some analyses suggest berberine produces effects similar to metformin on glucose metabolism and longevity biomarkers. Combining NAD+ precursors with berberine addresses both the NAD+ depletion and the glucose dysregulation that frequently co-occur in metabolically compromised individuals over 45.
Quercetin, beyond its senolytic properties, is a CD38 inhibitor — directly reducing the NAD+-consuming enzyme inflammation upregulates. That creates a synergistic relationship with NAD+ precursors: NMN or NR increase NAD+ production, quercetin reduces NAD+ consumption by CD38. The net effect on intracellular NAD+ should be additive. Apigenin (a flavone found in chamomile, parsley, celery) is another CD38 inhibitor with better bioavailability than quercetin in some formulations, and it’s increasingly showing up in NAD+ support stacks for that reason.
Chris stopped trying to evaluate the NMN by feel. He did something smarter: tracked his lifestyle changes systematically. Got a DEXA scan for body composition. Measured his VO2max. Got HbA1c and fasting insulin tested. Six months later, he had real data. His VO2max had improved substantially. His insulin sensitivity was better. His body composition had shifted meaningfully. He kept taking the NMN, but understood now that he couldn’t attribute any of these improvements specifically to it — and that understanding was itself worth something. The supplement might be contributing marginally. But the exercise, the sleep, the dietary changes were definitely contributing — measurably, directly, substantially. He had the data to prove the lifestyle effects even though the supplement’s contribution stayed forever unprovable. A useful realization: the supplement might add something at the margin, but the lifestyle factors below it are doing the heavy lifting, and they need to be in place first.
That epistemic honesty — knowing what you know and what you don’t — is the real sophistication in the longevity supplement space. The science of NAD+ is real. The current human evidence for supplemental precursors is limited but growing. The foundational lifestyle factors that support NAD+ biology naturally are established and available to everyone, no purchase required. Work through those first. Add NMN or NR as an adjunct once Layers 1-3 of the Longevity Operating System are solid, with appropriate expectations for a marginal boost rather than a transformative intervention. Maintain the intellectual honesty to know the difference between mechanism, animal evidence, and proof in humans — distinctions the longevity supplement industry has little financial incentive to help anyone maintain. For the broader longevity framework, see our guide to the Longevity Operating System.
The Practical Framework: Applying NAD NMN AntiAging Supplements In Real Life
References
Editorial StandardsCorrectionsMedical DisclaimerAbout Our ContentAffiliate DisclosureSite Map